Our Partners
We build long-term and short-term partnerships to combine George Medicines’ expertise with your areas of strength.
Building Partnerships for Global Impact
We aim to build both long-term and short-term partnerships with organisations of various types to combine George Medicines’ expertise with your areas of strength. Licensing, investment and research partnerships are all part of our focus.
Partner with George
Medicines on GMRx2
We seek to partner on the licensing and commercialization of GMRx2 in regions across the globe. Our triple single pill combination (SPC) for hypertension in adults has the potential to transform patient care worldwide, and we seek partners to help us achieve this goal.
FDA-approved in the United States as WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in 2025 and currently the first and only triple combination approved for initial therapy to treat hypertension in adults. To learn more about WIDAPLIK in marketed regions, and its full prescribing information including Boxed Warning, click here.
Key Data Points
For partners with cardiometabolic focus, this shift in emerging hypertension treatment guidelines and patient access creates a clear opportunity to change the healthcare landscape and be part of the next generation of combination therapies via this late stage, differentiated triple SPC.
Have Questions?
Global healthcare has a real opportunity to do better. Uncontrolled blood pressure and its direct links to cardiorenal and metabolic conditions remains one of the largest drivers of preventable death worldwide according to the United Nations. Many patients ultimately require multiple drugs to reach guideline BP targets. Dose escalation of multiple single medications can often result in poor adherence to these multi-pill regimens and even uncontrolled blood pressure.
GMRx2 is approved by the US FDA as WIDAPLIK for the treatment of hypertension, including as an initial treatment in adults likely to need multiple drugs to reach BP goals. It is planned for launch in the United States later in 2026 and additional regulatory filings are underway in other regions.
To learn more about WIDAPLIK in marketed regions, and its full prescribing information including Boxed Warning, click here.
The “ACT” Phase 3 clinical trial (NCT04518293)results published in The Lancet have shown that GMRx2 generated a greater reduction in blood pressure compared to dual combinations of hypertension medicines.
The “VERONICA” Phase 3 clinical trial results published in JAMA, have shown that in a physician guided dosing setting, GMRx2 improved reduction in blood pressure in both a home and clinical setting compared to the stepwise standard of care. This study conducted in Nigeria has equitable health potential in real world settings across other regions.
Current ESC guidelines highlight the importance of earlier use of combination therapy and single-pill combinations to improve control and adherence. Triple fixed-dose combinations for hypertension have been added to the WHO Essential Medicines List. GMRx2’s triple combination approach is consistent with these guidelines.
Hypertension control is foundational to reducing cardiovascular and renal events. The “TRIDENT” investigator-initiated Phase 3 clinical study results showing positive results that met its primary endpoint, where GMRx2 demonstrated significant and clinically meaningful reduction of recurrent stroke in patients with hypertension and a history of acute stroke due to intracerebral haemorrhage (ICH). George Medicines are also exploring rational combinations of GMRx2 with other cardiometabolic therapies.
GMRx2 uses three well-characterised components with established safety profiles. We’re able to provide partners with detailed CMC, quality and supply documentation under CDA and work to ensure reliable, scalable supply aligned to launch and growth plans.
Please contact our partnering lead, Gary Quashie:
Start a Partnership Discussion
Gary Quashie leads global partnering and alliance strategy for George Medicines, with a special focus on GMRx2. He works closely with our clinical, regulatory and market access teams to shape partnerships that align scientific, commercial and access objectives.
Gary often represents George Medicines at industry conferences (BIO International, BIO-Europe, ChinaBIO®, JPMorgan, Biotech Showcase, Jefferies, CPhI, PLG, AHA, ESC, ISH, ACC, ISC WSC etc.) and is happy to schedule a meeting in person or virtually.
